Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q125083> ?p ?o }
Showing triples 1 to 37 of
37
with 100 triples per page.
- Q125083 subject Q7215865.
- Q125083 subject Q8297710.
- Q125083 subject Q8413416.
- Q125083 subject Q8431759.
- Q125083 abstract "Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer. It is also being investigated as a therapy for diabetic kidney disease.Atrasentan failed a phase 3 trial for prostate cancer in patients unresponsive to hormone therapy. A second trial confirmed this finding.It is an endothelin receptor antagonist selective for subtype A (ETA). While other drugs of this type (sitaxentan, ambrisentan) exploit the vasoconstrictive properties of endothelin and are mainly used for the treatment of pulmonary arterial hypertension, atrasentan blocks endothelin induced cell proliferation.In April 2014, de Zeeuw et al. showed that 0.5 mg and 1.25 mg of atrasentan reduced urinary albumin by 35 and 38% respectively with modest side effects. Patients also had decreased home blood pressures (but no change in office readings) decrease total cholesterol and LDL. Patients in the 1.25 mg dose group had increased weight gain which was presumably due to increased edema and had to withdraw from the study more than the placebo or 0.5 mg dose group. Reductions in proteinuria have been associated with beneficial patient outcomes in diabetic kidney disease with other interventions but is not an accepted end-point by the FDA.The recently initiated SONAR trial will determine if atrasentan reduces kidney failure in diabetic kidney disease.".
- Q125083 atcPrefix "none".
- Q125083 casNumber "173937-91-2".
- Q125083 fdaUniiCode "V6D7VK2215".
- Q125083 iupacName "(2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid".
- Q125083 pubchem "159594".
- Q125083 thumbnail Atrasentan.svg?width=300.
- Q125083 wikiPageWikiLink Q1067506.
- Q125083 wikiPageWikiLink Q1128595.
- Q125083 wikiPageWikiLink Q12078.
- Q125083 wikiPageWikiLink Q18023163.
- Q125083 wikiPageWikiLink Q189159.
- Q125083 wikiPageWikiLink Q390709.
- Q125083 wikiPageWikiLink Q410789.
- Q125083 wikiPageWikiLink Q47912.
- Q125083 wikiPageWikiLink Q7215865.
- Q125083 wikiPageWikiLink Q8297710.
- Q125083 wikiPageWikiLink Q8413416.
- Q125083 wikiPageWikiLink Q8431759.
- Q125083 wikiPageWikiLink Q905664.
- Q125083 atcPrefix "none".
- Q125083 casNumber "173937".
- Q125083 iupacName "-4".
- Q125083 pubchem "159594".
- Q125083 unii "V6D7VK2215".
- Q125083 type ChemicalSubstance.
- Q125083 type Drug.
- Q125083 type ChemicalObject.
- Q125083 type Thing.
- Q125083 type Q8386.
- Q125083 comment "Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer. It is also being investigated as a therapy for diabetic kidney disease.Atrasentan failed a phase 3 trial for prostate cancer in patients unresponsive to hormone therapy. A second trial confirmed this finding.It is an endothelin receptor antagonist selective for subtype A (ETA).".
- Q125083 label "Atrasentan".
- Q125083 depiction Atrasentan.svg.